ERA | LRA | |||||
---|---|---|---|---|---|---|
MTXn = 217 | 10 mg ETNn = 208 | 25 mg ETNn = 207 | Placebon = 80 | 10 mg ETNn = 76 | 25 mg ETNn = 78 | |
DMARD, disease-modifying antirheumatic drug; ERA, early rheumatoid arthritis; ETN, etanercept; LRA, late rheumatoid arthritis; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis. | ||||||
Mean age (years) | 49 | 50 | 51 | 51 | 53 | 53 |
Women (%) | 75 | 75 | 74 | 76 | 84 | 74 |
Caucasian (%) | 88 | 84 | 86 | 89 | 96 | 94 |
Mean duration of RA(months) | 12 | 11 | 12 | 12 | 13 | 11 |
Rheumatoid factorpositive (%) | 89 | 88 | 87 | 78 | 80 | 78 |
Mean number of prior DMARDs | 0.6 | 0.5 | 0.5 | 3.0 | 3.4 | 3.3 |
Previous MTX (%) | — | — | — | 90 | 92 | 87 |
Patients receivingDMARDs before washout (%) | 24 | 25 | 23 | 48 | 46 | 45 |
Concomitant treatment at baseline (%) | ||||||
NSAIDs | 80 | 76 | 86 | 84 | 67 | 67 |
Corticosteroids | 41 | 42 | 39 | 58 | 66 | 81 |